Revisiting secondary prevention in coronary heart disease

Secondary prevention in coronary heart disease is the prevention of occurrence of recurrent coronary events after clinical diagnosis. High level of adherence to secondary prevention interventions, especially aggressive lifestyle changes and pharmacotherapy can lead to significant decline in recurrent coronary events. Both international and Indian studies have reported low adherence to such therapies. Evidence-based useful interventions include regular physical activity, yoga, intake of healthy diet, smoking and tobacco use cessation and weight management. Pharmacotherapeutic interventions useful are anti-platelet therapy, target oriented lipid lowering therapy with statins, beta blockers and angiotensin converting enzyme inhibitors in patients with impaired left ventricular function. Hypertension and diabetes management with control to targets is important. Novel strategies include use of anticoagulants, anti-inflammatory drugs, and triglyceride lowering for residual risk. Physician and patient level interventions using multifaceted educational, socioeconomic and technological innovations are important to promote life-long adherence to these strategies.


Introduction
Coronary heart disease (CHD) is most common type of cardiovascular disease and is the leading cause of death worldwide. Mortality due to CHD has decreased in developed countries but India and many other developing countries are still experiencing a significant increase in CHD morbidity and death rates. 1 Many studies have reported that Indians are more susceptible to coronary artery disease (CAD) and have a higher case-fatality rate than the western populations. 2 Advances in medical care and prevention have improved survival after the initial event but people with established CHD are at a high risk of subsequent cardiovascular events such as myocardial infarction, stroke, and cardiovascular death. Despite advances in pharmacological treatments and invasive procedures, quality of post-CHD management with better risk factor control and other pharmacological strategies and socioeconomic determinants of health remain independent predictors for fatality in patients with CAD. 3 Secondary prevention in coronary heart disease (CHD) is prevention of occurrence of recurrent coronary events after clinical diagnosis. 4 In the present article we shall focus on status of secondary prevention in India and highlight existing and emerging pharmacological therapies that can prevent recurrent coronary events. We also suggest interventions such as digital health and virtual team-based disease management to promote adherence to these lifelong therapies.

Status of secondary prevention in India
There is substantial evidence showing that secondary prevention through comprehensive risk factor modification has beneficial effects in patients with CAD, such as a decrease in mortality, reduction in recurrent cardiac events and better quality of life. 5 It has been suggested that adherence to four cardioprotective medicines: antiplatelet drugs, beta-blockers, angiotensin converting enzyme (ACS) inhibitors and lipid lowering statins can reduce 2 year mortality after acute coronary syndrome from 10% to about 2% (Fig. 1).
Guidelines from American College of Cardiology/American Heart Association (ACC/AHA), 6,7 European Society of Cardiology (ESC) 8 and almost all global CHD management guidelines have recommended aggressive risk factor management with adherence to healthy lifestyle and cardioprotective therapies in all patients who have been diagnosed with acute coronary syndrome (ACS) or have chronic coronary syndromes (CCS). 9,10 Status of secondary prevention is poor worldwide and multiple factors, predominantly social determinants of health such as rural location, poverty, illiteracy and low affordability and availability of supportive therapies are important. 3 In a low-resource setting like India, with poor focus on primary care, secondary prevention of CAD is a difficult task. 4 Delays in diagnosis, poor quality treatment, and poor adherence to primary and secondary prevention strategies are all symptoms of resource constraints. 11 The International Council of Cardiovascular Prevention and Rehabilitation (ICCPR) concluded global audit, felt the greatest need for cardiac rehabilitation (CR) exists in India.
The WHO-PREMISE study in 10 countries reported low adherence to drug therapies, particularly ACE inhibitors and statins, in developing compared to the more developed countries. 12 EURO-ASPIRE studies were performed in multiple European countries and initial surveys reported low adherence to healthy lifestyles and drug therapies. It was also reported that countries with lower human development index had significantly less adherence to healthy lifestyles (smoking cessation, physical acidity, healthy diet) and secondary preventive cardiac medicines (anti-platelets, beta blockers, ACE inhibitors and statins). 13 In high-income countries it has been reported that lower socioeconomic status patients have less access to cardiac rehabilitation and lower adherence to healthy lifestyles and secondary prevention drug therapies. 14 Prospective Urban Rural epidemiology (PURE) study reported a very low uptake of all the cardioprotective therapies in patients with known IHD and stroke in developing countries compared to more developed countries. 15 In the South Asian cohort of PURE study reported that low SES patients (low educational status or low wealth index) with IHD or stroke had the lowest consumption of various evidence based therapies at 4e5 years after diagnosis. 16 A nationwide prescription audit 17 and a Rajasthan state prescription audit 18 reported lower secondary prevention therapies in primary care clinics compared to IHD patients in secondary and tertiary care (Fig. 2) A prescription audit among stable IHD patients among a nationally representative sample in China reported that low socioeconomic status was independently associated with lower treatment rates for aspirin, clopidogrel, beta-blockers and statins. 19

Secondary prevention interventions
The main focus of secondary prevention is to prevent recurrent coronary events before symptoms appear and to prolong life. It includes disease management combining patient education, multidisciplinary team-based lifestyle management and therapeutic management. Lifestyle management focuses on tobacco (smoking and smokeless) cessation, increased physical activity, weight management and healthy dietary modification while therapeutic management focuses on standard and emerging cardioprotective medical therapies and percutaneous coronary interventions and surgical coronary revascularization. 20 Class of recommendations and level of evidence of use of various interventions are shown in Table 1.

Physical activity
Regular physical activity in any form is an important aspect of secondary prevention of CHD because it enhances exercise capacity, ameliorates co-morbid risk factors, and improves quality of life. 21 Exercise-based cardiac rehabilitation has been shown to lower all-cause and cardiac lethality compared to standard therapies. 21,22 All patients should be actively involved in 30e60 min of moderateintensity physical activity, such as biking or brisk walking. Ancillary physical activity lowers total cholesterol, triglyceride levels, and systolic blood pressure. Exercise-based cardiac rehabilitation programme can be started soon after an acute coronary syndrome or revascularization procedure. Before starting an intensive exercise routine, physicians should assess their patients' cardiovascular status by taking a physical activity history or performing an exercise test. Home based and mobile phone delivered exercise based rehabilitation has emerged to be equivalent to center based cardiac rehabilitation with added benefits of cost reduction and convenience. 23 Table 2 shows recommendations from various guidelines for diet. Dietary restrictions vary depending on the type of CAD risk factors. Adults who are at risk for high blood lipids should eat more fruits, leafy greens, whole grains, fish, and low-fat dairy products (healthy diet), while avoiding sugary drinks, sweets, and red meat. 21 Adults with high blood pressure problem should follow the same dietary restrictions but with low sodium levels. Dietary sodium restriction has also been recommended to reduce the risk of CAD in general population. 24 Sodium (in the form of salt) causes water retention, and increases sensitivity to blood pressure. Adopting a healthy eating pattern that spreads the daily intake of calories and nutrients over the entire day showed better compliance to the diet. Digital health tools delivered virtually have unique advantages in implementing and monitoring evidence based dietary modification. 25  Cardioprotective secondary prevention medicines (aspirin, beta-blockers, statins and ACE inhibitors/ARB) in primary, secondary and tertiary care in Rajasthan. 18 A. Sigamani and R. Gupta Indian Heart Journal 74 (2022) 431e440

Smoking/tobacco cessation
One of the most cost-effective interventions in secondary prevention is smoking and tobacco-use cessation. 21 All the guidelines recommend absolute tobacco cessation for CAD secondary prevention. Policy interventions are important and worldwide implementation of WHO Framework Convention for Tobacco Control (FCTC) can lead avoidance of millions of CAD events and can results in saving lakhs of lives. 26 At the individual level tobacco cessation can be achieved by patient education, nicotine replacement therapies, bupropion, psychotherapy and family support. Avoiding second-hand smoke is equally important. Using daily reminders, rewards for cutting down intake and periodic counselling on symptoms of withdrawal, offered through mobile phone increases success of sustained tobacco cessation.

Alcohol
A controversial issue in secondary prevention relates to alcohol use. 20 Light to moderate alcohol consumption has been linked to a reduced risk of CAD but the evidence is controversial. It is not recommended by any of the guidelines either for primary or secondary prevention. 4,15 A recent cohort study found that alcohol consumption increased the incidence of hypertension by 1.3-fold and CAD by 1.4-fold. Consumption of all amounts of alcohol, including those accepted by current national standards, is associated with increased cardiovascular risk, but there are considerable differences in risk between intake levels. 27 Building mental resilience and having control on impulsive behaviour reinforces moderation or avoidance of alcohol, specifically binge drinking. Mobile health platforms show promise in behaviour modification for positive change management.

Weight management
Obesity has been associated with an increased risk of CAD death rates, as well as an adverse influence on cardiac function and comorbid lifestyle factors. Maintaining an average weight with a body mass index (BMI) of 23e27 kg/m 2 and a waist circumference of <80 cm for women and <90 cm for men is suggested. The BMI should be measured at each counselling session, according to the American Heart Association (AHA), and then objective reviews and reliable counselling on weight loss programs should be provided. Balance of physical activities and dietary changes is required for long-term weight control, and modest weight loss is associated with changes in cardiac risk factors. 28 Use of mobile health platforms track daily physical activity duration and intensity. Having the physical instructor call and remind to perform daily tasks increase adherence to weight loss programs. Tracking changes in body parameters with integration of diet, mental wellness and stress management improve exercise tolerance in otherwise sedentary people.

Cardiac rehabilitation
Enrollment in a formal cardiac rehabilitation program is useful to learn the lessons for secondary prevention and better motivation. Studies in India have reported that there is low availability, affordability and awareness of cardiac rehabilitation facilities. 29 Comprehensive cardiac rehabilitation facility needs physicians, technicians, nurses and other health workers and could be expensive to maintain. Virtual cardiac rehabilitation delivered at home reduces cost, increases referral and uptake. Cochrane review comparing home based to centre based cardiac rehabilitation showed they were equivalent with added benefits to the patient. Studies from the UK and USA have shown that the virtual cardiac rehabilitation is effective. 30 Disease management through home based digital health tools in heart failure reduced hospital readmission rates and long-term morbidity. 31 No similar studies exist in India. A low-cost cardiac rehabilitation program has been developed using home-based follow-up following a hospital training protocol. 32

Pharmacotherapy
There has been a recent surge in understanding of approaches to long-term management of CAD. 33 Multiple approaches have been found to be useful and include multiple pillars of intervention. We hereby suggest six pillars of risk mitigation and interventions that focus on LDL cholesterol and residual cholesterol risk, triglyceride Diversity of plant-based foods Low animal source Balanced intake of unsaturated and saturated fats Reduced amounts of refined grains, highly processed foods, added sugars risk, thrombotic risk, vascular risk, hyperglycemia and diabetes risk, and inflammatory risk. The targets and therapeutic approaches to achieve targets are shown in Table 3. A combination of these drug-therapies is required to achieve improved outcomes in secondary prevention. Despite the use of all these pharmacological approaches and drugs there remains a substantial residual risk and more studies are required to identify interventions to overcome this risk.

Anti-platelet therapy
Antiplatelet therapy is essential part of medical regimen in acute coronary syndrome as well as for secondary prevention after stabilisation. Multiple randomised trials have clearly shown that dual antiplatelet therapy (DAPT) that includes aspirin and a P2Y 12 inhibitors should be taken for at least 12 months following acute coronary syndrome. It has also been shown in clinical trials that third generation P2Y 12 inhibitors (ticagrelor and prasugrel) show additional benefit in terms of decreased ischemic events compared to clopidogrel with an added cost of a slight increase in bleeding, however, the net outcomes are favourable for these drugs. In all the current guidelines, DAPT has typically been recommended for 12 months following acute coronary syndromes with ticagrelor and prasugrel generally preferred over clopidogrel. 34,35 The choice of drug as the third generation antiplatelet has been tested in a few trials. The recent MASTER DAPT trial showed that stopping dual antiplatelet therapy after 1 month was noninferior to continuing dual antiplatelet therapy for an additional 2 months in terms of net adverse clinical events and serious adverse cardiac or cerebral events. In addition, abbreviated dual antiplatelet therapy was superior to standard dual antiplatelet therapy in terms of clinically relevant major or minor bleeding. 36 The ISAR-REACT 5 trial 37 was a randomised, open-label comparison of prasugrel versus ticagrelor and reported higher rate of the composite primary end point (death, myocardial infarction, or stroke) at 1 year in patients randomised to ticagrelor (9$3 vs 6$9%; hazard ratio [HR] 1$36, 95% CI 1$09e1$70) with no significant difference in major bleeding. The 2020 ESC guidelines suggest a Class IIa (level of evidence B) recommendation for prasugrel over ticagrelor in patients with non ST elevation acute coronary syndrome who undergo PCI and are eligible for prasugrel (no prior stroke or transient ischaemic attack). 35 As for the consideration of single antiplatelet therapy following acute coronary syndrome, the TWILIGHT trial and a metanalysis of 32,000 patients found equivalent risk of MACE with early discontinuation of aspirin within 12 months. 38,39 Thus, randomised clinical trials and meta-analyses support dualantiplatelet therapy following an acute coronary event for at least 12 months and in those with high risk of bleeding, dual antiplatelet therapy for 1 month followed by ticagrelor (or prasugrel) as a single antiplatelet drug can be recommended. Symptom monitoring for potential bleeding complications is possible on digital mobile health platforms. This reduces anxiety, improves prescription confidence and avoids discontinuation of effective antiplatelet therapy.

Anti-coagulation therapy
Approximately 8e10% of patients undergoing for PCI have atrial fibrillation and other indication for an oral anticoagulant. 36 Several trials have evaluated different strategies and a meta-analysis of these trials reported lower rates of bleeding with a direct oral anticoagulant (DOAC)-based dual antithrombotic therapy than vitamin K agonist triple antithrombotic therapy, but with numerically greater rates of myocardial infarction and stent thrombosis without statistical significance. 36 Two large randomised trials that compared a DOAC (apixaban or edoxaban) and vitamin K agonist in this setting found lower rates of bleeding with the DOACs. 40,41 The 2020 ESC non-ST elevation-ACS guidelines, 42 recommend 1 week of triple antithrombotic therapy (or until hospital discharge) as a default strategy followed by dual antithrombotic therapy with a DOAC plus P2Y12 inhibitor (typically clopidogrel) until 1 year, at which point DOAC monotherapy can be considered. 29 Pill reminder short messaging services (SMS) based mobile health platforms improve compliance to anticoagulation therapy. Ensuring adherence reduces risk of stroke from atrial fibrillation. Rivaroxaban, an oral anticoagulant, has traditionally been used to reduce the risk of stroke and systemic embolism in people with nonvalvular atrial fibrillation. The COMPASS trial found that the combination of aspirin with low-dose rivaroxaban (2.5 mg) was effective in preventing major cardiovascular events such as strokes, heart attacks, and death in patients with stable CAD. 43

LDL cholesterol management
Various studies have shown that reducing the level of circulating atherogenic lipoproteins has a major effect on the risk of adverse cardiovascular events. A target LDL cholesterol level lower than 70 mg/dl with an optional target of 55 mg/dl in high-risk secondary prevention has been suggested by European guidelines. 44 Meta-analyses of multiple statin trials show a dosedependent relative reduction in cardiovascular events with LDL cholesterol lowering. The Cholesterol Treatment Trialists' (CTT) Collaborators performed a series of meta-analysis of cholesterol lowering (statins) from 2005 to 2020. Table 4 gives a summary of various statins and recommendations based on target LDL lowering. In the first report which evaluated 14 trials with 90,056 participants there was significant benefit in primary prevention. 45  44,49 Oral bempedoic acid has also emerged as a choice second-line drug in combination with a highdose statin. 51 Two monoclonal antibodies against PCSK9, evolocumab and alirocumab reduce LDL cholesterol by 50e70% and have shown major reductions in cardiovascular events in high-risk patients, including within 12 months of acute coronary syndromes. 52e54 Inclisiran, a small molecule based PCSK-9 inhibitor has also shown efficacy in reducing LDL cholesterol and effectiveness in reducing cardiovascular outcomes in CAD. 55 PCSK-9 inhibition is equally efficient in those with and without diabetes, with a 27% relative risk reduction in cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina or revascularization. All these drugs have been approved for use in CAD for LDL cholesterol reduction and outcome benefits. Guidelines recommend their use when LDL cholesterol remains >70 mg/ dL despite maximal dose statin plus ezetimibe, or if patients are statin intolerant and ezetimibe alone is ineffective in patients with established CAD. 44,49

Triglyceride lowering
Epidemiological studies have reported that raised serum triglycerides is a significant and independent CAD risk factor, but the association is weaker than for hypercholesterolaemia. Metaanalyses suggest that targeting triglycerides may reduce CAD in specific subgroups with high triglycerides and low HDL cholesterol. 56,57 REDUCE-IT, using high dose purified eicosapantenoic acid-icosapent ethyl, is the first trial to report significant benefits of triglyceride reduction combined with non-triglyceride mechanisms on cardiovascular outcomes. 57 This drug is now available in India and can be used in secondary prevention and high-risk primary prevention.

Lipoprotein(a) management
Raised lipoprotein(a) [Lp(a)] is now recognized as an important CAD risk factor in epidemiological studies, Mendelian randomized studies and genetic studies. 58 However, there is no randomized intervention study showing that reducing Lp(a) decreases CAD risk. At present there is no justification for screening the general population for Lp(a), but it may be considered in patients at moderate risk to refine risk evaluation or in subjects with a family history of premature CAD. 33,44,58

Cardiovascular protective agents
Cardioprotective agents work by improving left ventricular ejection fraction, restricting left ventricular hypertrophy, lowering myocardial oxygen demand (which is elevated in patients with CAD due to atherosclerosis) and vascular protection. These drugs include beta blockers, ACE inhibitors/ARBs, calcium channel blockers and nitrates.

Beta blockers
Beta blockers are first-line cardioprotective agents for patients with CAD. 4 These drugs reduce heart rate, increase diastolic filling time and lower cardiac contractility by restricting b1 and b2 adrenergic receptors. This significant inotropic and chronotropic effect reduces myocardial oxygen demand. Meta-analyses of multiple trials involving more than 24,000 patients who received beta blockers in the convalescent phase of STEMI have shown a 23% reduction in long-term mortality. 6 When beta blockers are administered early (<6 h) in the acute phase of infarction and continued in the chronic phase of treatment, some of the benefit may result from a reduction in infarct size. Patients with a relative contraindication to beta blockers (e.g., brady arrhythmias, atrioventricular blocks) should undergo a monitored trial of therapy in the hospital. Studies have suggested that beta-blocker therapy be continued for at least 2e3 years after acute coronary event. Long term use is indicated in patients with stable angina, recurrent unstable angina and congestive heart failure. 9

Inhibitors of renin-angiotensin-aldosterone system (RAAS)
Inhibition of RAAS is essential to prevent cardiac remodelling in post-acute coronary syndromes (STEMI or NSTEMI) patients. Treatment with ACE inhibitors such as captopril, enalapril, ramipril, trandolapril, or zofenopril for 1 month to 1 year in acute myocardial infarction improves left ventricular ejection fraction. 59 Findings from the HOPE trial showed that treatment with ramipril 10 mg/ day for 5 years reduces the incidence of death, myocardial infarction, cardiac arrest, and heart failure in patients with CAD, stroke, peripheral vascular disease, or diabetes without evidence of ejection fraction or heart failure. 60 The results of the EUROPA trial showed that treatment with perindopril at 8 mg/day for 4.2 years reduced cardiovascular events among patients with stable coronary heart disease. 61 Based on the results of these studies, ACE inhibitor (ramipril, perindopril) for all STEMI patients with ejection fraction <40%, renal dysfunction, or diabetes regardless of ejection fraction should be given if no contraindication exist. 42 The VALIANT trial results suggest that valsartan may be used as an alternative to an ACE inhibitor (in ACE inhibitor intolerant patients) for the longterm management of patients with left ventricular dysfunction after STEMI. 62 The STEP study demonstrated that intensive BP treatment (systolic BP target, 110 mmHg to <130 mmHg) benefits older hypertensive patients (60e80 years) and reduces the risk of cardiovascular events than standard treatment. 63 A recent metaanalysis of six randomised clinical trials including 27,400 hypertensive patients (aged !60) found that intensive systolic blood pressure lowering (systolic BP < 140 mm Hg) reduced the incidence of major adverse cardiovascular events by 21%. 64

Diabetes management
Proper management of type 2 diabetes is crucial to prevent complications in CAD secondary prevention. Two classes of drugs, SGLT2 inhibitors and GLP1 receptor agonists, have shown long term benefit in secondary prevention. 65 Results of meta-analyses of randomized controlled trials suggest that while GLP1 receptor agonists are more useful for primary prevention, SGLT2 inhibitors are better in secondary prevention, especially in patients with impaired left ventricular function. 66,67 Braunwald concluded that SGLT2 inhibitors are responsible for paradigm shifts in care of patients at high risk of heart failure-CAD secondary prevention, or having heart failure. 68 SGLT2 inhibition improves cardiovascular outcomes in patients with heart failure over a wide range of ejection fractions, regardless of whether the patients have type 2 diabetes. These drugs are also recommended as part of secondary as well as CAD primary prevention therapies.

Anti-inflammatory agents
Inflammation after acute coronary syndrome significantly contributes to recurrent ischemic events. Lipid lowering with rosuvastatin was effective in primary prevention with raised hsCRP levels (indicative of underlying inflammation). 69 Secondary prevention trials with a novel monoclonal antibody targeting interleukin-1b (canakinumab) reported significant benefit in secondary prevention. 70 Anti-inflammatory treatment with colchicine after acute coronary syndrome has recently shown some promise. In the COLCOT trial colchicine showed 23% reduction of MACE compared to placebo at 30 days in MI patients. 71 Similar findings were observed among patients with chronic coronary syndrome in the LoDoCo2 trial. 72 At present there is no recommendation for colchicine in CAD secondary prevention.

Adherence to secondary prevention
One of the most important aspects of secondary prevention is adherence to therapies. Adherence is defined as remaining attached to the medication regime and adequate adherence is use of therapies >80% of times. 73 Studies have reported that in chronic diseases only 50% patients are adherent to therapies at 12 months and just 20% take medications in appropriate dose. 74 Observational studies from all over the world, especially developing countries, have shown that most patients either not prescribed the full spectrum of lifestyle related interventions or pharmacological therapies. 19 Studies in US and North America have reported that less than 50% patients adhere to appropriate therapies at five-years post ACS while the rates are much lower (<10%) in developing and underdeveloped countries of Asia, Africa and Latin America. 15,75 There are numerous barriers to adherence and secondary prevention (Table 5). Although universally important, these factors are more relevant in middle-and low-income countries such as India. 3

Interventions to promote adherence
Outcomes of interventions to promote adherence are limited. A number of interventions directed at health care system, healthcare professionals and patients have been suggested (Table 6). There is some evidence that technology-based interventions, pharmacists' level interventions and health-worker based interventions are useful in promoting adherence and influence intermediate outcomes. 76 An important factor that promotes adherence in CHD primary and secondary prevention is self-management of risk factors. 21 Adherence to healthy lifestyles and pharmacological therapy in asymptomatic high-risk individuals is a herculean task and patient empowerment and personalized medicine to support lifelong  adherence to lifestyle changes and drug therapies can be useful. Technology-based strategies to promote adherence to healthy lifestyles and drug therapy are available and given the universality of smart-phone devices the potential for this personalized approach is enormous.

Digital health tools in secondary prevention
The digital health system is currently a thriving health care system, primarily for the management of chronic diseases, particularly after the COVID-19 pandemic. Digital healthcare systems can potentially address the failures of traditional treatments and therapies by efficiently sharing information with patients, providers, and decision makers, overcoming the barrier of geographic location to expand access to health care, delivering personalized care more precisely; reducing travel and treatment costs, improving compliance and patient adherence; and enabling remote monitoring of patients. 77 Digital health systems are divided into several categories according to the objectives and criteria, including telehealth and telemedicine, medical education, digital tools for diagnosis or decision making, devices to regulate or improve physiological functions, health informatics, and so on. 78 From the patient's perspective, digital health technologies offer valuable resources to develop self-management skills using diverse online platforms, mobile, social media, and wearable devices. 79 Despite the potential of healthcare delivery, the implementation and sustainability of digital healthcare interventions is very difficult to create a universal "digital prescription" for the management of chronic diseases due to the variable socio-cultural and economic status of people and the different laws and policies of different countries to adopt digital health care interventions. 80 Besides, digital health interventions are very complex and their practical implementation is very challenging due to various factors such as reliability/technical stability of electronic sensors and data transmissions; transparency of algorithms for autonomous decisions; access and usability; reorganization of workflow/infrastructure; poor implementation planning and security threats in data transmission and storage. 81 Because of these barriers, only a limited number of successful, evidence-based digital health interventions are beyond the pilot or feasibility stage ( Table 7). The efficacy of these digital health applications was assessed using different disease control outcome measures, such as disease symptoms, adverse events, exercise capacity, disease-related mortality, self-efficacy, quality of life assessment, economic outcomes and treatment adherence. 82 Large The study showed equivalent outcomes to centre-based CR in the modifiable coronary risk factors such as systolic and diastolic blood pressure, total cholesterol, waist circumference, and BMI. While the technology-assisted interventions did not improve anxiety and depression, they did improve exercise capacity (peak VO2 and 6MWT). The quality of life and psychological outcomes of the technology-assisted interventions were not superior to centre-based CR. The adherence to exercise training was similar to that of the centre-based CR. 3. Effectiveness of workplace interventions to reduce the risk for type 2 diabetes: A systematic review and meta-analysis. 85 Systematic review/ metaanalysis Workplace type 2 diabetes (T2D) prevention programs (DPP) This study included a total of five randomised controlled trials. DPP-based interventions were 3.85 times more likely to result in a weight loss of more than 5% ( efforts have also been made toward the overall goal of leveraging data to improve health information exchange and care coordination, but unfortunately, these efforts are significantly fragmented and provider-centric rather than patient-centric.

Conclusions
Secondary prevention in coronary heart disease (CHD) is crucial to reduce mortality and morbidity from this condition. High level of adherence to secondary prevention interventions including aggressive lifestyle changes and appropriate pharmacotherapy can lead to a significant decline in recurrent coronary events. Suggested interventions include regular physical activity, intake of healthy diet, smoking and tobacco use cessation, weight management and alcohol moderation. Pharmacotherapy interventions found useful are anti-platelet therapy (short-term dual and long-term single), target oriented lipid lowering therapy with statins (ezetimibe, bempedoic acid or PCSK9 inhibitors in statin non-responsive or intolerant), beta blockers (medium to long term) and angiotensin converting enzyme (ACE) inhibitors (angiotensin receptor blockers in ACE inhibitor intolerant). Novel strategies include use of anticoagulant and anti-inflammatory drugs, and lowering triglycerides and lipoprotein(a). Physician and patient level interventions are important to promote life-long adherence to these strategies. Digital health interventions delivered through adoption of technology and specialized follow ups by multidisciplinary teams have evidence for preventing hospital re-hospitalization and potentially reduce mortality in the long run. Despite the fact that the use of digital technologies is still in its early stages, continued efforts in this field may result in the introduction of evidence-based digital health applications for chronic disease management, which could be major disruptors to healthcare markets in the coming years.
Author declaration a) We the undersigned declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. b) We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. c) We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us. d) We agree to transfer copyright to the Indian Heart Journal upon the acceptance of the manuscript for publication. This review included eight studies, including five RCTs and three pilot or feasibility studies involving people with severe mental illness, cancer, CVD, COPD, and type 2 diabetes. Exercise behaviours (such as step count and exercise capacity) were significantly improved in four out of five RCTs. However, dietary behaviour was only evaluated in two studies with non-significant outcomes. 7. Strategies to promote the use of online health applications for early detection and raising awareness of chronic diseases among members of the general public: A systematic literature review. 89 Systematic review Online health applications for early detection and raising awareness of chronic diseases The review included 47 studies, 32 of which used a strategy to promote the use of their online intervention, and 27 of which reported strategies to keep users engaged. Various engagement strategies, particularly online advertisements and reminder messages, were found to improve user engagement, exposure to online health interventions, and the overall impact of such interventions. There was no formal evaluation of the effectiveness of the engagement strategies in any of the studies. 8. The effectiveness of electronic health interventions on blood pressure control, selfcare behavioural outcomes and psychosocial well-being in patients with hypertension: A systematic review and meta-analysis. 90 Systematic review/ metaanalysis e) We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.